DNRS 6501 Week 9 Assignment Psychological Disorders

Pathophysiology of Primary Diagnosis

Schizophrenia interferes with thought, perception, emotion, and behavior. The pathophysiology of schizophrenia is complex and unfamiliar, but genetic, neurological, and environmental factors are assumed. One of the key neurobiological theories is the dopamine hypothesis, which claims that schizophrenia is a result of the disruption in neurotransmission of dopamine in the brain. Specifically, the activation of mesolimbic dopamine D2 receptors could possibly result in the positive symptoms of schizophrenia, i.e., in hallucinations and delusions. On the other hand, negative symptoms that are associated with prefrontal brain dopamine D1 receptor hypoactivity include lethargy, social withdrawal, and cognitive impairment.

Another significant neurotransmitter is glutamate, which is associated with schizophrenia. The glutamate theory assumes that a dysfunction of the NMDA receptors leads to a disproportion in the excitation and inhibition of neurotransmission, which causes aspects of schizophrenia (Nakazawa and Sapkota, 2019). This is supported by the fact that NMDA receptor antagonists such as PCP and ketamine can produce schizophrenia-like symptoms in normal individuals.

Schizophrenia frequently leads to structural abnormalities of the brain. Neuroimaging reveals a reduction of gray matter in the frontal lobe of the brain (prefrontal cortex), the temporal lobes, and the hippocampus. Huge ventricles, which signify reduced volume of brain tissue, are prevalent. A change in the structure can be a neurodevelopmental issue leading to the disease. To a large extent, schizophrenia is genetic. It is believed that multiple, small-effect genes are risk-increasing. Dopamine and glutamate signaling, synaptic plasticity, and neurodevelopment are all risk genes involved. Environmental influences that raise the risk of schizophrenia development are prenatal infections, malnutrition, and psychological stress.

Causes

Risk Factors (genetic/ethnic/physical)

Schizophrenia has unknown causes, but there is a suspicion that a multifactorial interaction of genetic, environmental, and neurological variables is the cause. Genetic predisposition is great with a high heritability rate. Schizophrenic relatives are the individuals who contribute to the risk to a great extent (LE et al., 2020). There are several genetic risk factors that increase the risk, but there is no specific gene involved that makes someone schizophrenic. Rather, genetic changes and polymorphisms can make one vulnerable.

The environmental influences during the development of the brain can potentially increase the risk of schizophrenia. Exposure to prenatal influenza, rubella, and toxoplasmosis is associated with a higher risk of schizophrenia. The neural development of the fetus may be compromised by maternal deficiency of folate and may put the fetus at risk. There is a relationship between schizophrenia and birth issues such as hypoxia.

Schizophrenia symptoms can be caused and aggravated by psychosocial pressures and life experiences. Among the key risk factors are trauma, chronic stress, and childhood abuse, either physical/sexual. The risk of schizophrenia is elevated by substance abuse (particularly cannabis use during adolescence) and is particularly pronounced in those with a genetic predisposition.

Schizophrenia pathogenesis is also associated with neurobiological factors, including neurotransmitter and structural brain changes (Fišar, 2023). Pathophysiology of the disorder is associated with the dysfunction of dopamine, glutamate, GABAergic, and serotonergic systems. Structural brain abnormalities that could be signs of neurodevelopmental problems are reduced gray matter volume and increased ventricles.

There are several genetic, environmental, and psychosocial risk factors that increase the risk of schizophrenia. Genetics and propensity are two of the key risk factors. First-degree family members, or a parent and sibling of a schizophrenic patient, are the risk factors that make the general population more prone to schizophrenia. The genetic factor is highlighted by high schizophrenia concordance rates, particularly in monozygotic twins.

Prenatal and perinatal factors include those that pose a great risk of schizophrenia. The disease can be caused by infections, starvation, and toxins during pregnancy that affect the development of the fetus’s brain. Obstetric issues, such as hypoxia and premature labor, have also been associated with an increased level of risk.

Childhood and adolescent stressors and trauma are risk factors of schizophrenia (Inyang et al., 2022). Examples of adverse childhood experiences are risk factors of physical, emotional, and sexual abuse and neglect. The risk of schizophrenia is predisposed by substance abuse, particularly in the adolescent stage of cannabis use, particularly in those teenagers who have a genetic predisposition.

The risk factors include psycho social factors like social isolation, urbanization, and immigration. Social hardship and chronic stress may aggravate the symptoms of schizophrenia. Significant life changes, such as the loss of loved ones or a change in relationships, can be the cause of the illness in susceptible individuals.

Signs and Symptoms – Common presentation

How does the diagnosis impact each body system? Complications?

Schizophrenia is positive, negative, and cognitive. Positive symptoms involve hallucinations, delusions, and disorganization. Auditory hallucinations are a result of schizophrenia. There are voices that are not there, and they can comment or give orders to individuals. Delusions are unrelenting mistaken notions that are against the facts. Schizoid delusions are paranoid delusions of persecution and the delusions of great abilities.

Negative symptoms diminish or deprive one of normal functioning. Examples are decreased emotional and facial expressions and anhedonia, when individuals lose interest in previously rewarding activities. Alogia is low speech production, and avolition is a lack of drive and ability to initiate and sustain goal-oriented activities. Poor social withdrawal and reduced daily activity are typical undesired signs.

Attention, memory, and executive function issues refer to cognitive symptoms of schizophrenia (McCutcheon et al., 2022). Schizophrenia impacts decision making, cognition, and concentration. They are characterized by their inability to store and process data within a short period due to the weaknesses in their working memory. Such mental impairments cripple normal life and create chaos and incapacity.

Schizophrenia involves numerous body systems and causes psychological and physical complications. Schizophrenia is an abnormality of the brain that leads to a reduction in the volume of the gray matter and swelling of the ventricles. Such changes result in cognitive and emotional dysregulation of the disease.

Schizophrenia influences the endocrine system in a dysregulation of the HPA axis and elevation of cortisol levels. Dysregulation has the capability of boosting stress sensitivity and symptoms. The antipsychotic drugs used to treat schizophrenia may also have metabolic side effects, including weight gain, insulin resistance, and dyslipidemia, that increase the chances of developing metabolic syndrome and type 2 diabetes.

The cardiovascular system is largely affected by psychosis. Obesity, hypertension, and diabetes are risk factors that predominate in schizophrenia (McCutcheon et al., 2023). Antipsychotic drugs may cause cardiovascular complications by causing weight gain and metabolic abnormalities. Schizophrenia predisposes the heart to cardiovascular disorders, including coronary artery disease and heart failure, and also increases their mortality.

Schizophrenia disrupts the immune system, causing the body to become inflamed and unable to defend itself. The levels of pro-inflammatory cytokines that are high play a role in the development and progression of schizophrenia. This disproportion augments autoimmune disease and inflammation.

Schizophrenia and its treatment may affect the gastrointestinal system. Antipsychotic medicines may cause constipation and weight gain, exposing one to the risk of developing digestive problems. Gastrointestinal health is also impacted by schizophrenia because it reduces physical activities and diets.

Schizophrenia may impact the musculoskeletal system with a lack of physical activity and adverse effects of antipsychotics, including an increase in weight and osteoporosis. Patients with schizophrenia experience more chronic pain, including back and joint pain, which lessens their quality of life and physical disability.

Some diseases can present as symptoms of schizophrenia, and they need to be diagnosed differently to treat them accordingly. Schizophrenia and mood disorders, such as depression and bipolar disorder, have common symptoms with schizoaffective disorder. Schizophrenia is known to bring mood swings and psychotic symptoms, which entail hallucinations and delusions.

Another diagnosis is psychotic bipolar disorder. Psychotic symptoms, including hallucinations and delusions, may be caused by the hemodynamic bipolar illness (Chakrabarti and Singh, 2022). Bipolar illness and schizophrenia are differentiated by different mood episodes. Schizophrenia like symptoms may be presented in major depressive disorder with psychosis. In extreme depression, delusions and hallucinations can be experienced. These psychotic symptoms are mood-congruent, and they only appear during bouts of depression as opposed to permanent psychotic symptoms of schizophrenia.

The other important differential diagnosis is psychosis caused by substances. Psychotic symptoms such as schizophrenia may be brought about by cannabis, amphetamines, cocaine, and hallucinogens. Psychosis caused by substances requires a thorough history of substance use in order to be differentiated from simple psychotic diseases. Schizophrenia can be like temporal lobe epilepsy, delirium, and neurodegenerative disorders such as Alzheimer’s. The disorders may lead to hallucinations, delusions, and cognitive impairments. These disorders need to be eliminated, and thorough medical and neurological tests must be conducted to give a proper diagnosis.

The clinical assessment of schizophrenia involves a robust clinical assessment, comprising a psychiatric history, mental state test, and DSM-5. The clinical interview focuses on the symptoms, the time, the severity of the patient, and his/her daily functioning. The clinical picture may be supplemented with the help of collateral information provided by family or caregivers. Neuroimaging in the diagnosis of schizophrenia is not commonly used, but it can be used to exclude structural abnormalities of the brain or other neurological disorders that can develop psychotic symptoms. Schizophrenia neurobiological alterations can be determined by the methods of functional imaging (Positron Emission Tomography (PET) and functional MRI (fMRI)), although they are employed primarily in research (Ray et al., 2024).

Lab tests are conducted to eliminate medical conditions such as schizophrenia. This requires a Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), and thyroid tests to determine thyroid issues, electrolyte issues, and metabolic illness. Substance use screening is considered to determine substance-induced psychosis as opposed to simple psychotic illnesses. Schizophrenia-related cognitive deficits can be evaluated using psychological tests, particularly the cognitive evaluations. Attention, memory, executive function, and other cognitive abnormalities can be explained by tests that show that schizophrenia has functional abnormalities.

Treatment of schizophrenia involves pharmacotherapy, psychotherapy, psychosocial interventions, and medical support. Antipsychotic drugs are important in the pharmacotherapy of schizophrenia. The first-generation and second-generation anti-psychotics are popular: olanzapine, haloperidol, chlorpromazine, risperidone, and aripiprazole. Significant reduction in the extrapyramidal and improved side effects render atypical antipsychotics preferred.

Antipsychotic drugs reduce positive symptoms of schizophrenia by blocking dopamine receptors, in particular, D 2 receptors. They do not, however, have a similar impact on the other neurotransmitter systems; thus, they vary in their therapy and side effects. Medication choice depends on the symptoms exhibited by the patient, history of response to treatment, side effects, and comorbidities. Note any adverse effects in the patients, including weight gain, metabolic changes, and difficulties in mobility, and change in the treatment strategy when necessary.

Psychotherapy is required in the treatment of schizophrenia. The program of Cognitive Behavioral Treatment (CBT) will be helpful in addressing the cognitive distortions and negative thinking patterns of the disorder. CBT is useful in coping, social functioning, and symptoms. Family therapy and psychoeducation involve the family members in the treatment and offer knowledge and support to cope with the disease.

Social, vocational, and quality of life are improved by means of psychosocial interventions. The reintegration of schizophrenia patients into society and the achievement of objectives is achieved through the employment of the patients with the support of social skills and rehabilitation. Assertive Community Treatment (ACT) teams and case management teams organize the treatment and assist in finding the resources.

There should be medical aid in managing schizophrenia. Referrals to psychiatrists, psychologists, social workers, and occupational therapists are often necessary in order to provide full care. Psychotherapy and support are provided by psychologists and therapists, whereas medication and evaluation of treatment outcomes are done by psychiatrists. Case managers and social workers assist with resources, healthcare, and social and practical needs.

Patients with treatment-resistant schizophrenia might require additional interventions. Clozapine is a useful antipsychotic drug in the treatment of schizophrenia that is resistant to medication treatment, but it should be regularly reviewed due to the level of agranulocytosis. In the case of extreme scenarios, especially when there is a risk of self or other injury, Electroconvulsive Therapy (ECT) can be considered. Transcranial Magnetic Stimulation (TMS) and Deep Brain Stimulation (DBS) represent the two emerging neuromodulation techniques that can be utilized to address the unresolved symptoms.